PROCEPT BioRobotics Corporation

PRCT

Equity

ISIN US74276L1052 / Valor 113304787

NASDAQ (2025-04-01)

USD 57.09-2.01%

PROCEPT BioRobotics Corporation
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

PROCEPT BioRobotics Corporation is a pioneering medical technology company that specializes in the development and commercialization of robotic surgical systems. The company's flagship product, the AquaBeam Robotic System, represents a significant advancement in the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). This innovative system is distinguished by its use of Aquablation therapy, a unique, image-guided, and heat-free approach that offers a minimally invasive alternative to traditional surgical procedures. By leveraging robotic precision and real-time imaging, the AquaBeam Robotic System aims to improve patient outcomes, reduce recovery times, and provide a safer, more effective treatment option for millions of men worldwide suffering from BPH.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

PROCEPT BioRobotics Corporation reported a total revenue of $58.4 million for the third quarter of 2024, marking a significant increase of 66% compared to the same period in 2023. This growth was primarily driven by increased system sales, higher average selling prices, and a rise in handpiece and consumable revenue.

U.S. Market Performance

In the U.S. market, PROCEPT BioRobotics Corporation achieved revenue of $52.2 million for the third quarter of 2024, representing a 62% growth compared to the prior year period. The company sold 45 robotic systems at an average selling price of approximately $432,000, contributing to this substantial increase.

International Revenue Surge

Internationally, PROCEPT BioRobotics Corporation saw a remarkable revenue increase of 122% for the third quarter of 2024, reaching $6.2 million. This growth highlights the company's expanding global presence and successful market penetration outside the United States.

Improved Gross Margin

The company reported a record gross margin of 63.2% for the third quarter of 2024, up from 53.8% in the same period of the previous year. This improvement was attributed to better overhead absorption and increased average selling prices of U.S. robotic systems.

Financial Outlook

PROCEPT BioRobotics Corporation has increased its fiscal year 2024 revenue guidance to a range of $222.5 million to $223.0 million, reflecting a growth of 63% to 64% over the previous year. Additionally, the company has raised its gross margin guidance to 61% and adjusted EBITDA loss guidance to $60.0 million, indicating a positive outlook for the remainder of the year.

Summarized from source with an LLMView Source

Key figures

21.5%1Y

%3Y

%5Y

Performance

61.7%1Y

62.1%3Y

62.1%5Y

Volatility